These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37236833)

  • 1. Neuromelanin: Its role in the pathogenesis of idiopathic Parkinson's disease and potential as a therapeutic target.
    Mitra R; Premraj L; Khoo TK
    Parkinsonism Relat Disord; 2023 Jul; 112():105448. PubMed ID: 37236833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
    Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanin and Neuromelanin: Linking Skin Pigmentation and Parkinson's Disease.
    Krainc T; Monje MHG; Kinsinger M; Bustos BI; Lubbe SJ
    Mov Disord; 2023 Feb; 38(2):185-195. PubMed ID: 36350228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis.
    Enochs WS; Sarna T; Zecca L; Riley PA; Swartz HM
    J Neural Transm Park Dis Dement Sect; 1994; 7(2):83-100. PubMed ID: 7710667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease.
    Gonzalez-Sepulveda M; Compte J; Cuadros T; Nicolau A; Guillard-Sirieix C; Peñuelas N; Lorente-Picon M; Parent A; Romero-Giménez J; Cladera-Sastre JM; Laguna A; Vila M
    Brain; 2023 Mar; 146(3):1040-1052. PubMed ID: 36717986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The enigma of neuromelanin in Parkinson's disease substantia nigra.
    Youdim MB; Ben-Shachar D; Riederer P
    J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
    Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromelanin in Parkinson's Disease: from Fenton Reaction to Calcium Signaling.
    Knörle R
    Neurotox Res; 2018 Feb; 33(2):515-522. PubMed ID: 28879408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis.
    Carballo-Carbajal I; Laguna A; Romero-Giménez J; Cuadros T; Bové J; Martinez-Vicente M; Parent A; Gonzalez-Sepulveda M; Peñuelas N; Torra A; Rodríguez-Galván B; Ballabio A; Hasegawa T; Bortolozzi A; Gelpi E; Vila M
    Nat Commun; 2019 Mar; 10(1):973. PubMed ID: 30846695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromelanin and Parkinson's disease.
    Marsden CD
    J Neural Transm Suppl; 1983; 19():121-41. PubMed ID: 6321645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined enrichment of neuromelanin granules and synaptosomes from human substantia nigra pars compacta tissue for proteomic analysis.
    Plum S; Helling S; Theiss C; Leite REP; May C; Jacob-Filho W; Eisenacher M; Kuhlmann K; Meyer HE; Riederer P; Grinberg LT; Gerlach M; Marcus K
    J Proteomics; 2013 Dec; 94():202-206. PubMed ID: 23917253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
    Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
    Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxic Feedback Loop Involving Iron, Reactive Oxygen Species, α-Synuclein and Neuromelanin in Parkinson's Disease and Intervention with Turmeric.
    Jansen van Rensburg Z; Abrahams S; Bardien S; Kenyon C
    Mol Neurobiol; 2021 Nov; 58(11):5920-5936. PubMed ID: 34426907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New face of neuromelanin.
    Double KL; Halliday GM
    J Neural Transm Suppl; 2006; (70):119-23. PubMed ID: 17017518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
    Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
    Herrera A; Muñoz P; Steinbusch HWM; Segura-Aguilar J
    ACS Chem Neurosci; 2017 Apr; 8(4):702-711. PubMed ID: 28233992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuromelanin of the human substantia nigra: an update.
    Zucca FA; Basso E; Cupaioli FA; Ferrari E; Sulzer D; Casella L; Zecca L
    Neurotox Res; 2014 Jan; 25(1):13-23. PubMed ID: 24155156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.